Digital Biomarkers Come of Age: Pharma Adoption, FDA Acceptance, and Trial Design Evolution

Digital biomarkers are rapidly moving from experimental endpoints to validated measures capable of transforming drug development and precision medicine. As AI, sensors, and behavioral analytics mature, pharma and techbio companies are building the frameworks to make these signals clinically credible and regulatory sound. The challenge now lies in standardizing validation, ensuring interoperability, and proving value across R&D, clinical, and commercial domains - while convincing internal stakeholders, regulatory reviewers, and payers that wearable-derived data and app-based measurements can inform critical development decisions with the same confidence as traditional clinical endpoints.

This masterclass explores how leading organizations are integrating digital biomarkers into trial design, regulatory submissions, and post-market evidence generation. Experts will discuss emerging FDA and EMA expectations for digital endpoint validation, evolving payer perspectives on digital biomarker evidence, and how to connect signal accuracy with economic and clinical relevance. 

Join us to discuss:

• What validation and evidence frameworks define a regulatory-grade digital biomarker that FDA and EMA will accept in submissions?

• How are digital biomarkers transforming trial design, patient stratification, and outcome measurement in ways that reduce development time and costs?

• How can pharma, techbio, and payers align around standards that make digital endpoints both clinically credible and commercially reimbursable?